A Phase II Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)

Trial Profile

A Phase II Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)

Suspended
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Brain metastases; Breast cancer; Lung cancer
  • Focus Therapeutic Use
  • Acronyms CaBaMet
  • Most Recent Events

    • 26 Jun 2017 Planned End Date changed from 1 Sep 2017 to 1 Apr 2018.
    • 06 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2017.
    • 06 Mar 2017 Status changed from recruiting to suspended because After a recruitment of more than 2 years, only 8 patients have been registered.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top